Search
01/02/2022
Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma
Dlouhy, I, Karube, K, Enjuanes, A, Salaverria, I, Nadeu, F, Ramis-Zaldivar, JE, Valero, JG, Rivas-Delgado, A, Magnano, L, Martin-Garcia, D, Perez-Galan, P, Clot, G, Rovira, J, Jares, P, Balague, O, Gine, E, Mozas, P, Briones, J, Sancho, JM, Salar, A, Mercadal, S, Alcoceba, M, Valera, A, Campo, E, Lopez-Guillermo, A. Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma. BRITISH JOURNAL OF HAEMATOLOGY. 2022; 196(3)DOI:10.1111/bjh.17858. PMID:34632572. IF:6.500(Q1/3D).
01/02/2022
Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/ TCF3-PBX1 treated with measurable residual disease-oriented protocols
Ribera, J, Granada, I, Morgades, M, Gonzalez, T, Ciudad, J, Such, E, Calasanz, MJ, Mercadal, S, Coll, R, Gonzalez-Campos, J, Tormo, M, Garcia-Cadenas, I, Gil, C, Cervera, M, Barba, P, Costa, D, Ayala, R, Bermudez, A, Orfao, A, Ribera, JM. Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/ TCF3-PBX1 treated with measurable residual disease-oriented protocols. BRITISH JOURNAL OF HAEMATOLOGY. 2022; 196(3)DOI:10.1111/bjh.17844. PMID:34549416. IF:6.500(Q1/3D).
01/02/2022
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials
Allan, JN, Shanafelt, T, Wiestner, A, Moreno, C, O'Brien, SM, Li, JL, Krigsfeld, G, Dean, JP, Ahn, IE. Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials. BRITISH JOURNAL OF HAEMATOLOGY. 2022; 196(4)DOI:10.1111/bjh.17984. PMID:34865212. IF:6.500(Q1/3D).
01/02/2022
Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase Ill MabCute study
Rule, S, Barreto, WG, Briones, J, Carella, AM, Casasnovas, O, Pocock, C, Wendtner, CM, Zaja, F, Robson, S, MacGregor, L, Tschopp, RR, Nick, S, Dreyling, M. Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase Ill MabCute study. HAEMATOLOGICA. 2022; 107(2)DOI:10.3324/haematol.2020.274803. PMID:34134469. IF:10.100(Q1/2D).
01/02/2022
Detection of azole resistance in Aspergillus fumigatus complex isolates MALDI-TOF mass
Zvezdanova, ME, Arroyo, MJ, Mendez, G, Candela, A, Mancera, L, Rodriguez, JG, Serra, JL, Jimenez, R, Lozano, I, Castro, C, Lopez, C, Munoz, P, Guinea, J, Escribano, P, Rodriguez-Sanchez, B, Sánchez-Reus F.. Detection of azole resistance in Aspergillus fumigatus complex isolates MALDI-TOF mass. CLINICAL MICROBIOLOGY AND INFECTION. 2022; 28(2)DOI:10.1016/j.cmi.2021.06.005. PMID:34147673. IF:14.200(Q1/1D).
01/02/2022
MiR-125b downregulates macrophage scavenger receptor type B1 and reverse cholesterol transport
Hueso, M, Grinan, R, Mallen, A, Navarro, E, Purqueras, E, Goma, M, Sbraga, F, Blasco-Lucas, A, Revilla, G, Santos, D, Canyelles, M, Julve, J, Escola-Gil, JC, Rotllan, N. MiR-125b downregulates macrophage scavenger receptor type B1 and reverse cholesterol transport. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2022; 146DOI:10.1016/j.biopha.2021.112596. PMID:35062066. IF:7.500(Q1/1D).